KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CEO Thomas Andrew Crockett sold 5,627 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $10.14, for a total transaction of $57,057.78. Following the completion of the sale, the chief executive officer now owns 128,050 shares […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) insider Christopher Yea sold 2,604 shares of KalVista Pharmaceuticals stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $10.14, for a total value of $26,404.56. Following the sale, the insider now directly owns 37,310 shares of the company’s stock, valued […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 3,280,000 shares, a growth of 17.1% from the April 15th total of 2,800,000 shares. Currently, 14.0% of the shares of the company are sold […]